- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02232204
Sleep and Ventricular Arrhythmias Study (SAVE)
Sleep in Cardiac Patients With Implantable Cardioverter Defibrillators (ICD)
Study Overview
Status
Intervention / Treatment
Detailed Description
Participants will be asked to review the informed consent form and consent to the study prior to beginning any study procedure.
There are six phases of this study: (1) an in-person interview, (2) an in-home single night sleep recording, (3) a two-week baseline period, (4) a 4-week treatment period, (5) a follow-up period immediately after the completion of treatment, (6) and a two-week follow-up period 3-months after the treatment period.
During the interview, participants will be asked questions about their sleep, cardiac, and ICD history. Participants will then visit the University of Florida for a medical history and will be connected to machinery to monitor their sleep. Participants will return home to sleep while still connected to the machine and will return the machine to the University of Florida the next day. A third visit will consist of completing questionnaires and a computerized neurocognitive performance battery to assess several areas of cognitive functioning. Participants will then go home and with brief daily diaries to complete for two weeks while also wearing an actigraph (wristwatch-like device) that measures arm movements to detect sleep/wake during that time.
Participants will then be randomized to (a) the brief cognitive behavioral therapy for insomnia (CBTi) in ICD patients group or (b) the waitlist control group. The treatment consists of 2 weeks of in-person therapy and 2 weeks of therapy conducted over the telephone. Participants assigned to waitlist control will be offered therapy at no cost at the end of the study. Throughout the 4 treatment weeks, participants in both groups will be asked to complete daily sleep diaries.
A follow-up period consisting of two weeks, during which participants will wear the actigraph and complete daily sleep diaries, will take place immediately after treatment completion. Participants will travel to the University two times during this follow-up period in order to pick-up and then return the actigraph and sleep diaries, and will once again complete the questionnaires and neurocognitive testing battery at the end of the 2nd visit. A final follow-up period will occur 3-months following treatment, which will involve visits to the University to pick up the daily sleep diaries and actigraph for sleep monitoring, and then returning these items after completion 2-weeks later. Upon returning the diary and actigraph, participants will complete questionnaires and then be debriefed by study personnel.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida Aging
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Current ICD implantation (single or dual lead ICD, ICD and pacemaker)
- Diagnosis of insomnia
- No sleep medications for at least 1 month, or stable on medications for at least 6 months
- Willing to be randomly assigned to treatment
- Able to read and understand English
Exclusion Criteria:
- Sleep disorder other than insomnia
- Significant medical condition other than cardiac disease
- Severe untreated psychopathology
- Neurological disorder
- Cognitive impairment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CBT for Insomnia in ICD Patients (CBT-I-ICD)
Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress.
A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
|
Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress.
A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
|
No Intervention: Waitlist Control (WLC)
Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments.
After the final follow-up assessment, they will be offered the opportunity to receive CBT-I-ICD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in subjective and objective sleep
Time Frame: Change from baseline to the two study follow-ups (immediately and 3-months following treatment)
|
Sleep diary and actigraphy-derived sleep parameters (averaged over each 14-day data collection period at baseline, post-treatment, and at 3-month follow-up) including: time to fall asleep (sleep onset latency), wake time during the night (waketime after sleep onset), total sleep time, amount of time spent in bed sleeping (sleep efficiency), total nap time, and sleep quality rating.
|
Change from baseline to the two study follow-ups (immediately and 3-months following treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in psychological functioning
Time Frame: Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
|
Changes in reported symptoms of anxiety and depression as assessed by questionnaires from baseline to immediately and 3 months following treatment.
|
Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
|
Change in daytime functioning
Time Frame: Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
|
The change in reported insomnia impact, fatigue, and sleepiness as assessed by questionnaires from baseline to immediately and 3 months following treatment.
|
Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
|
Change in quality of life
Time Frame: Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
|
The change in reported health-related quality of life as assessed by questionnaires from baseline to immediately and 3 months following treatment.
|
Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
|
Change in cardiac functioning
Time Frame: Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
|
The change in device-recorded incidence of ventricular arrhythmia from baseline to immediately and 3 months following treatment.
|
Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
|
Change in device adjustment
Time Frame: Change from baseline to the two follow-up periods (immediately and 3-months following treatment
|
The change in reported shock anxiety and device-specific acceptance as assessed by questionnaires from baseline to immediately and 3 months following treatment.
|
Change from baseline to the two follow-up periods (immediately and 3-months following treatment
|
Change in cognitive functioning
Time Frame: Change from baseline to immediately after treatment
|
The change in computer-recorded cognitive functioning in the domains of executive control, reasoning, working memory, attention, and reaction time as assessed from baseline to immediately following treatment.
|
Change from baseline to immediately after treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christina S McCrae, PhD, University of Florida
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 157-2008
- R21HL087831 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
-
Butler HospitalSunovionCompleted
Clinical Trials on CBT for Insomnia in ICD Patients (CBT-I-ICD)
-
VA Office of Research and DevelopmentTerminatedSleep Initiation and Maintenance Disorders | Marijuana AbuseUnited States
-
University of RochesterNational Institute of Nursing Research (NINR); National Institute of Neurological... and other collaboratorsCompleted
-
Johns Hopkins UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedOsteoarthritis | Sleep Initiation and Maintenance DisordersUnited States
-
American University of Beirut Medical CenterRecruiting
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI)RecruitingChronic Insomnia | Cancer-related Problem/Condition | Cancer-Related SyndromeUnited States
-
Stanford UniversityNational Institute of Mental Health (NIMH)CompletedDepression | InsomniaUnited States
-
Dartmouth-Hitchcock Medical CenterCompletedInflammatory Bowel Diseases | InsomniaUnited States
-
The University of Hong KongKowloon Hospital, Hong KongCompleted
-
University of CalgaryUniversity of ManitobaCompleted
-
Indiana UniversityIndiana Clinical and Translational Sciences InstituteTerminatedChronic Pain | InsomniaUnited States